
403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Worldsymposiumtm 2026 To Honor Global Leaders In Science, Innovation, And Patient Advocacy
(MENAFN- EIN Presswire) EINPresswire/ -- WORLDSymposium 2026 will recognize three distinguished individuals whose leadership and vision have advanced the understanding, treatment, and advocacy of lysosomal diseases. The awards will be presented during the 22nd annual WORLDSymposium, February 2-6, 2026, at the Manchester Grand Hyatt San Diego. Registration is now open for this premier international scientific meeting.
Catalyst Award
The 2026 Catalyst Award honors Professor Michael H. Gelb, PhD, for pioneering scientific innovations that have transformed newborn screening for lysosomal disorders. Dr. Gelb's development of enzymatic assays enabled global implementation of expanded newborn screening, revolutionizing early detection and improving outcomes for families worldwide.
Roscoe O. Brady Award
WORLDSymposium is pleased to announce Peter Marks, MD, PhD, as the recipient of the 2026 Roscoe O. Brady Award. During his tenure at the U.S. Food and Drug Administration, Dr. Marks redefined collaboration across the rare-disease ecosystem, championing innovation, transparency, and meaningful engagement between researchers, industry, and patient advocates. His leadership has affected regulatory science on a global scale and expanded access to life-changing therapies for individuals with rare diseases.
Patient Advocate Leader (PAL) Award
Bob Stevens, Group CEO of the MPS Society and Rare Disease Research Partners (RDRP), will receive the 2026 Patient Advocate Leader (PAL) Award. A globally respected leader and rare-disease parent, Mr. Stevens has spent more than 25 years advancing care, research, and access for lysosomal disease communities through visionary advocacy, data-driven collaboration, and an unwavering commitment to patient-centered progress.
Looking Ahead: Late-Breaking Science
In addition to these award recognitions, WORLDSymposium 2026 will feature a Late-Breaking Science session highlighting the most current discoveries and clinical advances in lysosomal research. The Call for Late-Breaking Abstracts will be open November 1, 2025, through December 1, 2025, and offers investigators an opportunity to share emerging data with an international audience of scientists, clinicians, and patient advocates.
Attend in San Diego
Award honorees will be formally recognized during WORLDSymposium 2026, taking place February 2–6, 2026, in San Diego, California. The meeting happens only once a year and will convene global experts for five days of scientific sessions, poster presentations, and collaborative discussions to drive progress in lysosomal disease research and care.
Early registration is encouraged, as in-person attendance is expected to reach capacity. Learn more and register at worldsymposia.
About WORLDSymposium
WORLDSymposium (We're Organizing Research on Lysosomal Diseases) is an annual global medical education conference focused on lysosomal diseases. Now in its 22nd year, the meeting brings together 2,000 researchers, clinicians, patient advocates, and industry professionals from over 50 countries to exchange knowledge and advance the field. The 2026 Annual Scientific Meeting will be held February 2-6, 2026, at the Manchester Grand Hyatt in San Diego, California.
Catalyst Award
The 2026 Catalyst Award honors Professor Michael H. Gelb, PhD, for pioneering scientific innovations that have transformed newborn screening for lysosomal disorders. Dr. Gelb's development of enzymatic assays enabled global implementation of expanded newborn screening, revolutionizing early detection and improving outcomes for families worldwide.
Roscoe O. Brady Award
WORLDSymposium is pleased to announce Peter Marks, MD, PhD, as the recipient of the 2026 Roscoe O. Brady Award. During his tenure at the U.S. Food and Drug Administration, Dr. Marks redefined collaboration across the rare-disease ecosystem, championing innovation, transparency, and meaningful engagement between researchers, industry, and patient advocates. His leadership has affected regulatory science on a global scale and expanded access to life-changing therapies for individuals with rare diseases.
Patient Advocate Leader (PAL) Award
Bob Stevens, Group CEO of the MPS Society and Rare Disease Research Partners (RDRP), will receive the 2026 Patient Advocate Leader (PAL) Award. A globally respected leader and rare-disease parent, Mr. Stevens has spent more than 25 years advancing care, research, and access for lysosomal disease communities through visionary advocacy, data-driven collaboration, and an unwavering commitment to patient-centered progress.
Looking Ahead: Late-Breaking Science
In addition to these award recognitions, WORLDSymposium 2026 will feature a Late-Breaking Science session highlighting the most current discoveries and clinical advances in lysosomal research. The Call for Late-Breaking Abstracts will be open November 1, 2025, through December 1, 2025, and offers investigators an opportunity to share emerging data with an international audience of scientists, clinicians, and patient advocates.
Attend in San Diego
Award honorees will be formally recognized during WORLDSymposium 2026, taking place February 2–6, 2026, in San Diego, California. The meeting happens only once a year and will convene global experts for five days of scientific sessions, poster presentations, and collaborative discussions to drive progress in lysosomal disease research and care.
Early registration is encouraged, as in-person attendance is expected to reach capacity. Learn more and register at worldsymposia.
About WORLDSymposium
WORLDSymposium (We're Organizing Research on Lysosomal Diseases) is an annual global medical education conference focused on lysosomal diseases. Now in its 22nd year, the meeting brings together 2,000 researchers, clinicians, patient advocates, and industry professionals from over 50 countries to exchange knowledge and advance the field. The 2026 Annual Scientific Meeting will be held February 2-6, 2026, at the Manchester Grand Hyatt in San Diego, California.

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Casper Network Advances Regulated Tokenization With ERC-3643 Standard
- Forex Expo Dubai Wins Guinness World Recordstm With 20,021 Visitors
- Superiorstar Prosperity Group Russell Hawthorne Highlights New Machine Learning Risk Framework
- Freedom Holding Corp. (FRHC) Shares Included In The Motley Fool's TMF Moneyball Portfolio
- Versus Trade Launches Master IB Program: Multi-Tier Commission Structure
- Ozzy Tyres Grows Their Monsta Terrain Gripper Tyres Performing In Australian Summers
Comments
No comment